Kiniksa Pharmaceuticals International, plc's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Quarterly earnings show how the company is performing and help investors understand profitability trends.
Quarterly earnings show how the company is performing and help investors understand profitability trends.
Board elections show who leads the company; shareholders voted to keep these directors through 2029.
This agreement limits a major shareholder's voting power, protecting other investors from dilution.
Leadership changes affect company direction; Tessari will advise at $450/hour up to 20 hours monthly.
Stocky reads Kiniksa Pharmaceuticals International, plc's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Kiniksa Pharmaceuticals International, plc's most recent tracked filing was a 10-Q on 28 Jul 2026: Kiniksa reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.